| Literature DB >> 31988745 |
I-Chen Hung1, Hao-Yuan Chang2,3, Aristine Cheng4, Mei-Wen Chen3, An-Chi Chen1, Ling Ting1, Yeur-Hur Lai2,5, Jann-Tay Wang1,4, Yee-Chun Chen1,4, Wang-Huei Sheng4,6.
Abstract
Background: Inadequate hospital cleaning may contribute to cross-transmission of pathogens. It is important to implement effective cleaning for the safe hospital environment. We conducted a three-phase study using human factors engineering (HFE) approach to enhance environmental cleanliness.Entities:
Keywords: ATP bioluminescence assay; Carriage incidence of multidrug-resistant organism; Environmental cleaning and disinfection; Fluorescent marker; Human factors engineering
Mesh:
Substances:
Year: 2020 PMID: 31988745 PMCID: PMC6966902 DOI: 10.1186/s13756-020-0677-1
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Human Factors Engineering (HEF)-Informed Environmental Cleaning and Disinfection Strategies for Improving Terminal Cleaning and Disinfection
| Work system elements | HFE-informed intervention |
|---|---|
| People | Environmental service workers (ESWs) education (eg, strengthening wipe off practices, when to change cleaning cloths and mop heads, and reminders not to miss the high-touch surfaces.) |
| Tasks | Redesign and simplify the workflow of terminal cleaning and disinfection on the basis of ergonomics principles (eg, clean one side of mattress then walk to the other side to clean the other part of mattress, avoid excessive extension of body) |
| Tools and technologies | Redesign the regular method of disinfectant dilution (Additional file Design a checklist-form reminder with high-touch surfaces photographs (Additional file |
| Organization Internal environment External environment | Using a media to publicize the efforts of the ESWs in infection prevention, encourage all of people to maintain a clean environment in the hospital, and make understanding of time allowed to clean room. |
Fig. 1Change in the mean terminal cleaning and disinfection (TCD) score of the fluorescent marker (FM), ATP bioluminescence assay (ATP), and aerobic colony count (ACC) evaluation methods in the pre-intervention (phase 1), intervention (phase 2), and analytical phases (phase 3)
Terminal Cleaning and Disinfection Score of the Fluorescent marker, ATP, and ACC Methods by Phases (n = 84)
| Method | Phase 1(a) | Phase 2(b) | Phase 3(c) | Post-hoc (Bonferroni)a | |
|---|---|---|---|---|---|
| Mean ± SD | |||||
| Fluorescent marker | 39.4 ± 17.6 | 74.6 ± 17.6 | 85.4 ± 10.0 | < .001 | b > a***, c > a***, c > b*** |
| ATP | 63.5 ± 13.4 | 84.8 ± 11.1 | 86.6 ± 9.6 | < .001 | b > a***, c > a*** |
| ACC | 91.7 ± 6.3 | 96.5 ± 4.0 | 95.6 ± 5.1 | .002 | b > a**, c > a* |
NOTE. ATP ATP bioluminescence assay, ACC aerobic colony count, SD standard deviation
a*P < .05, **P < .01, ***P < .001
Terminal Cleaning and Disinfection Score of the Fluorescent marker, ATP, and ACC Methods by Ward Types
| Method | Medical wards (a) | Surgical wards (b) | ICUs (c) | Post-hoc (Bonferroni)a | |
|---|---|---|---|---|---|
| Mean ± SD | |||||
| Fluorescent marker | |||||
| Phase 1 | 39.0 ± 10.7 | 23.0 ± 13.3 | 56.5 ± 10.5 | < .001 | a > b*, c > a**, c > b*** |
| Phase 2 | 74.7 ± 16.8 | 68.9 ± 21.6 | 80.4 ± 13.6 | .339 | – |
| Phase 3 | 87.3 ± 8.9 | 80.4 ± 12.9 | 88.1 ± 6.7 | .196 | – |
| ATP | |||||
| Phase 1 | 68.0 ± 7.2 | 57.0 ± 12.7 | 64.8 ± 17.6 | .195 | – |
| Phase 2 | 89.3 ± 6.4 | 87.4 ± 11.9 | 77.0 ± 11.2 | .031 | a > c* |
| Phase 3 | 88.0 ± 5.0 | 93.0 ± 6.3 | 78.5 ± 11.0 | .002 | b > c* |
| ACC | |||||
| Phase 1 | 90.3 ± 6.6 | 88.9 ± 6.1 | 96.1 ± 3.9 | .027 | c > b* |
| Phase 2 | 93.7 ± 4.6 | 98.1 ± 2.6 | 98.0 ± 2.6 | .015 | b > a*, c > a* |
| Phase 3 | 95.3 ± 3.6 | 96.3 ± 4.5 | 95.2 ± 7.1 | .885 | – |
NOTE. ATP ATP bioluminescence assay, ACC aerobic colony count, ICUs intensive care units, SD standard deviation
a*P < .05, **P < .01, ***P < .001
The Incidence of Carriage and Healthcare-Associated Infection of MDRO per 1000 Patient-Days were Determined in the Pre-intervention Period and During the Intervention Period
| The incidence of MDRO per 1000 patient-days | ||||
|---|---|---|---|---|
| Pre-intervention perioda | Intervention periodb | |||
| Carriage | ||||
| Overall | 28 | 4.1 (564/136794) | 3.6 (507/140860) | .03 |
| VRE | 1.8 (253/136794) | 1.3 (184/140860) | < .001 | |
| MRSA | 1.3 (178/136794) | 1.2 (171/140860) | .55 | |
| CRABC | 1.0 (133/136794) | 1.1 (152/140860) | .41 | |
| General wards | 19 | 3.7 (421/114141) | 3.4 (403/117894) | .29 |
| VRE | 1.8 (209/114141) | 1.3 (152/117894) | < .001 | |
| MRSA | 1.2 (136/114141) | 1.2 (147/117894) | .75 | |
| CRABC | 0.7 (76/114141) | 0.9 (104/117894) | .07 | |
| ICUs | 9 | 6.3 (143/22653) | 4.5 (104/22966) | .01 |
| VRE | 1.9 (44/22653) | 1.4 (32/22966) | .19 | |
| MRSA | 1.9 (42/22653) | 1.0 (24/22966) | .03 | |
| CRABC | 2.5 (57/22653) | 2.1 (48/22966) | .39 | |
| Healthcare-associated infection | ||||
| Overall | 28 | 0.3 (47/136794) | 0.4 (62/140860) | .23 |
| General wards | 19 | 0.3 (30/114141) | 0.4 (44/117894) | .17 |
| ICUs | 9 | 0.8 (17/22653) | 0.8 (18/22966) | .97 |
NOTE. MDRO multiple-drug resistant organism, including vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and carbapenem-resistant Acinetobacter baumannii complex (CRABC)
aJuly 2016 to January 2017
bMarch 2017 to September 2017